Abstract:Background Idiopathic pulmonary fibrosis (IPF) is a rare and serious disease characterized by progressive lung-function loss. Limited evidence has been published on the impact of lung-function loss on subsequent patient outcomes. This study examined change in forced vital capacity (FVC) across IPF patients in the 6 months after diagnosis and its association with clinical and healthcare resource utilization (HRU) outcomes in a real-world setting in the U.S. Methods A retrospective chart review was conducted of patients diagnosed with IPF by U.S. pulmonologists. Patient eligibility criteria included: 1) 40 years or older with a confirmed date of first IPF diagnosis with high-resolution computed tomography and/or lung biopsy between 01/2011 and 06/2013; 2) FVC results recorded at first diagnosis (±1 month) and at 6 months (±3 months) following diagnosis. Based on relative change in FVC percent predicted (FVC%), patients were categorized as stable (decline <5 %), marginal decline (decline ≥5 % and <10 %), or significant decline (decline ≥10 %). Physician-reported clinical and HRU outcomes were assessed from ~6 months post-diagnosis until the last contact date with the physician and compared between FVC% change groups. Multivariable Cox proportional-hazards models were constructed to assess risk of mortality, suspected acute exacerbation (AEx), and hospitalization post-FVC% change. Generalized estimating equations were used to account for multiple patients contributed by individual physicians. Results The sample included 490 IPF patients contributed by 168 pulmonologists. The mean (SD) age was 61 (11) years, 68 % were male, and the mean (SD) baseline FVC% was 60 % (26 %). 250 (51 %) patients were categorized as stable, 98 (20 %) as marginal decline, and 142 (29 %) as significant decline. The mean (SD) observation time was 583 (287) days. In both unadjusted analysis and multivariable models, significantly worse clinical outcomes and increased HRU were observed with greater lung-function decline. Conclusions These findings suggest that nearly half of IPF patients experienced decline in FVC% within ~6 months following IPF diagnosis. Greater FVC% decline was associated with an increased risk of further IPF progression, suspected AEx, mortality, and higher rate of HRU. Management options that slow FVC decline may help improve future health outcomes in IPF.

Detection of Idiopathic Pulmonary Fibrosis Disease Progression using Respiratory Oscillometry

The impact of respiratory reactance in oscillometry on survival in patients with idiopathic pulmonary fibrosis

Impulse Oscillometry System As an Alternative Diagnostic Method for Chronic Obstructive Pulmonary Disease

Relevance Analysis of Clinical and Lung Function Parameters Changing and Prognosis of Idiopathic Pulmonary Fibrosis.

Diagnostic value of impulse oscillometry in chronic obstructive pulmonary disease: a multicentre, retrospective, observational study

Clinical application of oscillometry in respiratory diseases: an impulse oscillometry registry

Use of 6-min walk distance to predict lung transplant-free survival in fibrosing non-IPF interstitial lung diseases

Use of 6‐minute walk distance to predict lung transplant‐free survival in fibrosing non‐IPF interstitial lung diseases

Relationship between peripheral airway function and patient-reported outcomes in COPD: a cross-sectional study

Idiopathic pulmonary fibrosis disease progression: a dynamic quantitative chest computed tomography follow-up analysis

Evaluation of Respiratory Impedance in Patients with Chronic Obstructive Pulmonary Disease by an Impulse Oscillation System.

Forced Oscillation Technique for Sensitive Detection of Early-Stage Chronic Obstructive Pulmonary Disease

Clinical Value of Impulse Oscillometry in Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis

Assessing the prognostic value of respiratory oscillometry in patients with difficult-to-treat asthma

Proportion and predictors of FVC decline in patients with interstitial lung disease

Lung function trajectory in progressive fibrosing interstitial lung disease

Change in forced vital capacity and associated subsequent outcomes in patients with newly diagnosed idiopathic pulmonary fibrosis

Pursuing Clinical Predictors and Biomarkers for Progression in ILD: Analysis of the Pulmonary Fibrosis Foundation (PFF) Registry

Application Value of Broadband 3-Dimensional Impulse Oscillometry in COPD.

Oscillometry as a Predictor of Exercise Tolerance in COPD

Research progress in the application of impulse oscillometry and fractional exhaled nitric oxide in idiopathic pulmonary fibrosis